MRK News Friday, November 20, 2026 +0.65 Positive

Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal Adenocarcinoma

Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal Adenocarcinoma

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed